Unknown PHASE2 INTERVENTIONAL NCT00129155

MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Sponsor: Hospices Civils de Lyon

Conditions Allogeneic Transplantation Hematological Malignancies

Interventions treosulfan

Updated 6 times since 2017 Last updated: Oct 3, 2007 Started: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00129155, this PHASE2 trial focuses on Allogeneic Transplantation and Hematological Malignancies and remains ongoing. Sponsored by Hospices Civils de Lyon, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE2
Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospices Civils de Lyon

Data source: Hospices Civils de Lyon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lyon, France